Prevalence of dog erythrocyte antigen (DEA) 1 amongst the dog blood donors at Tamil Nadu veterinary and animal sciences university animal blood bank (TABB), India

The study of dog blood groups has increased in the last years. Inherited antigens on the RBC surface define blood groups. There are 7 blood groups in the canine DEA system. Amongst these blood groups, DEA 1 blood group is highly immunogenic and consequently has greater clinical importance. A retrospective study was conducted in 125 purebred and mongrel dog blood donors at the TANUVAS Animal Blood Bank, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai, India during the period from January 2010 to January 2011. Donor dogs were screened and typed for the presence of DEA 1 using the monoclonal antibody kit. The prevalence of DEA 1 was 61.6%. The prevalence of DEA 1 dogs in India agrees with most of the data reported in the literature

Appropriate referral and selection of patients with chronic pain for spinal cord stimulation: European consensus recommendations and e-health tool

Background: Spinal cord stimulation (SCS) is an established treatment for chronic neuropathic, neuropathic-like and ischaemic pain. However, the heterogeneity of patients in daily clinical practice makes it often challenging to determine which patients are eligible for this treatment, resulting in undesirable practice variations. This study aimed to establish patient-specific recommendations for referral and selection of SCS in chronic pain. Methods: A multidisciplinary European panel used the RAND/UCLA Appropriateness Method (RUAM) to assess the appropriateness of (referral for) SCS for 386 clinical scenarios in four pain areas: chronic low back pain and/or leg pain, complex regional pain syndrome, neuropathic pain syndromes and ischaemic pain syndromes. In addition, the panel identified a set of psychosocial factors that are relevant to the decision for SCS treatment. Results: Appropriateness of SCS was strongly determined by the neuropathic or neuropathic-like pain component, location and spread of pain, anatomic abnormalities and previous response to therapies targeting pain processing (e.g. nerve block). Psychosocial factors considered relevant for SCS selection were as follows: lack of engagement, dysfunctional coping, unrealistic expectations, inadequate daily activity level, problematic social support, secondary gain, psychological distress and unwillingness to reduce high-dose opioids. An educational e-health tool was developed that combines clinical and psychosocial factors into an advice on referral/selection for SCS. Conclusions: The RUAM was useful to establish a consensus on patient-specific criteria for referral/selection for SCS in chronic pain. The e-health tool may help physicians learn to apply an integrated approach of clinical and psychosocial factors. Significance: Determining the eligibility of SCS in patients with chronic pain requires careful consideration of a variety of clinical and psychosocial factors. Using a systematic approach to combine evidence from clinical studies and expert opinion, a multidisciplinary European expert panel developed detailed recommendations to support appropriate referral and selection for SCS in chronic pain. These recommendations are available as an educational e-health tool (https://www.scstool.org/)

Does COVID-19 Cause the Spillover Volatility of Steel and Tube Companies Stock Returns and BSE Metal Index

COVID-19 epidemic has been impacted the growth of economic and development of industries. The steel and tube companies also suffered and down surges the financial stability and its growth uncertain. The study use the event of COVID-19 to exhibits the spillover and investors decision. The study examines the Covid-19 cause the spillover volatility of steel and tube companies stock returns and BSE metal The study focused on the steel and tube companies’ stocks returns. This study helps traders and investors of steel and tube companies’ stock returns and supports to take better investing decisions in this sector. Stock market Price and BSE metal indices were collected for the time period of two years pre-COVID [from 2018 to 2019] and two years post-COVID [from 2020 to 2021]. This study revealed that changes in the stock Prices of certain companies, namely Ratnamani Metal and Welspun Corp caused changes in the BSE metal index, before the pandemic, but post pandemic it has been found that the changes in BSE metal index caused changes in APL Apollo and Ratnamani Metal. In terms of volatility, the BSE metal index and certain selected companies were found to be highly volatile, while others were moderately volatile, both pre and post pandemic. The conclusion of the research article is that the stock returns of steel and tube companies were found to be lower than the risk, making them not suitable for long-term investment, but suitable for traders and speculators to make good profits, both pre and post COVID

Profile of the capsaicin 8% patch for the management of neuropathic pain associated with postherpetic neuralgia: safety, efficacy, and patient acceptability

Muhammad Laklouk,1 Ganesan Baranidharan2 1Department of Anaesthesia, Bradford Teaching Hospitals NHS Foundation Trust, 2Leeds Pain and Neuromodulation Centre, Leeds Teaching Hospitals NHS Trust, Seacroft Hospital, Leeds, UK Abstract: Capsaicin is a naturally occurring irritant active ingredient found in hot peppers. It is a ligand for transient receptor potential channel vanilloid receptors, which are found in nociceptive nerve terminals in the skin. Initial exposure to topical capsaicin leads to excitation of these receptors, release of vasoactive mediators, erythema, intense burning, pain, and thereafter desensitization of sensory neurons resulting in inhibition of pain transmission. Capsaicin 8% has been licensed for the treatment of postherpetic neuralgia pain in recent years. A single application of high-concentration capsaicin for 60 minutes for postherpetic neuralgia has been robustly evaluated. Capsaicin 8% patches are applied to the most painful areas of healthy skin and allowed to remain for 60 minutes. Treatment can be repeated every 90 days if the pain persists or returns. The patches are usually applied in specialist pain clinics where patients can be pretreated and monitored. Health care staff need to take certain precautions before administering these patches to avoid unintentional contact. Common adverse effects of the capsaicin 8% patch are transient mild-to-moderate self-limiting application-site burning, pain, erythema, pruritus, papules, swelling, dryness, and hypertension. To manage local pain from capsaicin application, the skin is pretreated with a local anesthetic such as topical lidocaine or an oral analgesic such as oxycodone for up to 5 days. A transient increase in pain is usually seen within 48 hours of patch application before the pain-relieving effect starts. Systemic absorption is minimal and clinically insignificant. The nature of administration and relatively high cost of capsaicin patches can significantly limit their use to a small number of patients with severe refractory symptoms. This review highlights recent evidence related to the use and effectiveness of the 8% capsaicin patch for Postherpetic Neuralgia and discusses its safety and side-effect profiles. Keywords: capsaicin, efficacy, safety, tolerability, high-dose patch, postherpetic neuralgi